Bioactive compounds of natural origin are gaining increasing popularity. High biological activity and bioavailability, beneficial effects on health and safety of use are some of their most desirable features. Low production and processing costs render them even more attractive. Microorganisms have been used in the food, medicinal, cosmetic and energy industries for years. Among them, microalgae have proved to be an invaluable source of beneficial compounds. Haematococcus pluvialis is known as the richest source of natural carotenoid called astaxanthin. In this paper, we focus on the cultivation methods of this green microalga, its chemical composition, extraction of astaxanthin and analysis of its antioxidant, anti-inflammatory, anti–diabetic and anticancer activities. H. pluvialis, as well as astaxanthin can be used not only for the treatment of human and animal diseases, but also as a valuable component of diet and feed.
Astaxanthin is gaining recognition as a natural bioactive component. This study aimed to test whether astaxanthin could protect adipose-derived stromal stem cells (ASCs) from apoptosis, mitochondrial dysfunction and oxidative stress. Phaffia rhodozyma was used to extract astaxanthin, whose biocompatibility was tested after 24, 48 and 72 h of incubation with the cells; no harmful impact was found. ASCs were treated with optimal concentrations of astaxanthin. Several parameters were examined: cell viability, apoptosis, reactive oxygen levels, mitochondrial dynamics and metabolism, superoxide dismutase activity, and astaxanthin’s antioxidant capacity. A RT PCR analysis was performed after each test. The astaxanthin treatment significantly reduced apoptosis by modifying the normalized caspase activity of pro-apoptotic pathways (p21, p53, and Bax). Furthermore, by regulating the expression of related master factors SOD1, SOD2, PARKIN, PINK 1, and MFN 1, astaxanthin alleviated the oxidative stress and mitochondrial dynamics failure caused by EMS. Astaxanthin restored mitochondrial oxidative phosphorylation by stimulating markers associated with the OXPHOS machinery: COX4I1, COX4I2, UQCRC2, NDUFA9, and TFAM. Our results suggest that astaxanthin has the potential to open new possibilities for potential bio-drugs to control and suppress oxidative stress, thereby improving the overall metabolic status of equine ASCs suffering from metabolic syndrome.
The endoplasmic reticulum (ER) fulfills essential duties in cell physiology, and impairment of this organelle’s functions is associated with a wide number of metabolic diseases. When ER stress is generated in the adipose tissue, it is observed that the metabolism and energy homeostasis of the adipocytes are altered, leading to obesity-associated metabolic disorders such as type 2 diabetes (T2D). In the present work, we aimed to evaluate the protective effects of Δ9-tetrahydrocannabivarin (THCV, a cannabinoid compound isolated from Cannabis sativa L.) against ER stress in adipose-derived mesenchymal stem cells. Our results show that pre-treatment with THCV prevents the subcellular alteration of cell components such as nuclei, F-actin, or mitochondria distribution, and restores cell migration, cell proliferation and colony-forming capacity upon ER stress. In addition, THCV partially reverts the effects that ER stress induces regarding the activation of apoptosis and the altered anti- and pro-inflammatory cytokine profile. This indicates the protective characteristics of this cannabinoid compound in the adipose tissue. Most importantly, our data demonstrate that THCV decreases the expression of genes involved in the unfolded protein response (UPR) pathway, which were upregulated upon induction of ER stress. Altogether, our study shows that the cannabinoid THCV is a promising compound that counters the harmful effects triggered by ER stress in the adipose tissue. This work paves the way for the development of new therapeutic means based on THCV and its regenerative properties to create a favorable environment for the development of healthy mature adipocyte tissue and to reduce the incidence and clinical outcome of metabolic diseases such as diabetes.
Background: Liquid formulations for equine gastric use should retain coating-related properties during acidity, pepsin exposure, dilution, and shear.Aims/objectives: To compare a bimodal hyaluronic acid–chitosan (HA–Ch) liquid formulation with a hyaluronic acid (HA) control under equine simulated gastric fluid (ESGF) and in Caco-2 assays.Methods: Rheology at 37°C was assessed before and after ESGF exposure. Flow behavior was evaluated over 1–100 s⁻¹, and viscosity stability for 60 min at 50 s⁻¹. Caco-2 assays included MTS, scratch wound closure, and RT-qPCR.Results: After ESGF exposure, the consistency coefficient was higher for HA–Ch than HA (3.427 ± 0.033 vs. 2.884 ± 0.028; n = 3). Final viscosity after continuous shear was 562.27 ± 8.89 mPa·s for HA–Ch and 244.37 ± 24.45 mPa·s for HA. Viscosity retention was 96.74 ± 3.63% and 77.85 ± 9.04%, respectively, and AUC was 32925.90 ± 627.26 versus 16869.50 ± 516.76 mPa·s·min. At 6.25%, 22-h metabolic activity was 100.1 ± 1.44% for HA–Ch and 102.8 ± 5.07% for HA. HA–Ch increased wound closure at 3 h (14.15 ± 4.49% vs. 4.40 ± 4.15% control) and 6 h (28.00 ± 7.38% vs. 15.84 ± 6.40% control). RT-qPCR markers did not differ between groups.Conclusion: In this in vitro equine gastric model, chitosan increased the rheological stability of bimodal HA in ESGF and during continuous shear. HA–Ch remained compatible with Caco-2 cells and supported early epithelial wound closure under the tested conditions.